



# Posttraumatic Growth and Coping Strategies Among Patients With Head and Neck Cancer: Do Approach Coping and Avoidant Coping Predict Posttraumatic Growth Over Time?

## OPEN ACCESS

### Edited by:

Gema T. Ruiz-Parraga, University of Malaga, Spain

#### Reviewed by:

Annunziata Romeo, University of Turin, Italy HeeSoon Lee, Bowling Green State University, United States

### \*Correspondence:

Mohammad Farris Iman Leong Bin Abdullah farris@usm.my

### Specialty section:

This article was submitted to Health Psychology, a section of the journal Frontiers in Psychology

Received: 29 May 2021 Accepted: 30 September 2021 Published: 26 October 2021

### Citation:

Nik Jaafar NR, Abd Hamid N, Hamdan NA, Rajandram RK, Mahadevan R, Mohamad Yunus MR, Zakaria H and Leong Bin Abdullah MFI (2021) Posttraumatic Growth and Coping Strategies Among Patients With Head and Neck Cancer: Do Approach Coping and Avoidant Coping Predict Posttraumatic Growth Over Time? Front. Psychol. 12:716674. doi: 10.3389/fpsyg.2021.716674 Nik Ruzyanei Nik Jaafar<sup>1</sup>, Norhaliza Abd Hamid<sup>2</sup>, Nur Amirah Hamdan<sup>2</sup>, Rama Krsna Rajandram<sup>3</sup>, Raynuha Mahadevan<sup>1</sup>, Mohd Razif Mohamad Yunus<sup>4</sup>, Hazli Zakaria<sup>1</sup> and Mohammad Farris Iman Leong Bin Abdullah<sup>2\*</sup>

<sup>1</sup>Department of Psychiatry, Universiti Kebangsaan Malaysia Medical Centre, Cheras, Malaysia, <sup>2</sup>Lifestyle Science Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia, <sup>3</sup>Department of Oral and Maxillofacial Surgery, Universiti Kebangsaan Malaysia Medical Centre, Cheras, Malaysia, <sup>4</sup>Department of Otorhinolaryngology, Universiti Kebangsaan Malaysia Medical Centre, Cheras, Malaysia

Despite an enormous number of studies addressing the importance of posttraumatic growth (PTG) among cancer patients, the literature lacks data regarding how different coping strategies affect PTG among head and neck cancer (HNC) patients over time. This longitudinal study investigated the PTG trend and coping over 5-7 months among a cohort of HNC patients within the first year after their diagnosis. It determined an association between coping strategies and PTG over time. The study's HNC respondents were administered a socio-demographic and clinical characteristics guestionnaire during their baseline assessments. Additionally, the Malay versions of the "PTG Inventory-Short Form" (PTGI-SF) and the "Brief Coping Orientation to Problems Experienced Inventory" (Brief COPE) were administered during respondents' baseline assessments and follow-up assessments (5-7 months after the baseline assessments). In total, 200 respondents reported an increasing PTG trend and approach coping (active coping, planning, positive reframing, acceptance, emotional support, and instrumental support) and a decreasing trend of avoidant coping (self-distraction and denial) over time. Two approach coping strategies (acceptance and planning) significantly increased PTG while denial was the only avoidant coping strategy that significantly lowered PTG, after controlling for sociodemographic and clinical characteristics, over time. Our study's findings identified the need to incorporate psychosocial interventions that enhance approach coping and reduce avoidant coping into HNC patients' treatment regimes.

Keywords: posttraumatic growth, approach coping, avoidant coping, head and neck cancer, longitudinal study, Malaysia

1

# INTRODUCTION

Cancer is generic term describing a group of diseases that feature abnormal cell growth beyond cells' boundaries, invading adjoining tissues and spreading the abnormal cells to other organs. Cancer is a leading cause of death globally, accounting for 10 million mortalities in 2020 (World Health Organization, 2021). In Malaysia, cancer is equally common, with a 5-year prevalence of 128,018 cases and an incidence of 48,639 cases in 2020. Head and neck cancer (HNC) is the fourth most common cancer among men in Malaysia, representing 7.4% of all cancer cases in the country in 2020 (Globocan, 2020). Due to its association with mortality, cancer is perceived as a traumatic event or a highly intense stressor among patients that is capable of inducing posttraumatic growth (PTG). PTG is a psychological development that results from a struggle with an intense life stressor or trauma. However, PTG does not develop directly from the traumatic experience. Initially, occurrence of a traumatic event may shatter the assumptive world of a person (a general set of beliefs and assumptions of the person about the surrounding world, which act as guidance for actions and understanding of the causes and reasons of events that happens as well as serves as a sense of meaning and purpose in life). In order to rebuild a new assumptive world after the occurrence of trauma, cognitive rebuilding must take place where there is a search for meaning out of the traumatic experience by incorporating the traumarelated information into reconstruction of the new assumptive world of the person. As a result of these cognitive processes, PTG that develop in a person is a transformative phenomenon which leads to an improved qualitative change of functioning, which surpass the level of functioning before the struggle with the traumatic event or crisis. There may be a curvilinear relationship between the degree of psychological distress and PTG, in which a person with a low level of stress may not be sufficient to trigger PTG compared with someone who experience a trauma, whereas another person with very high degree of trauma may be too overwhelmed to trigger development of PTG (Tedeschi and Calhoun, 1996, 2004; Calhoun et al., 2000).

Posttraumatic growth has been reported in HNC patients (Ho et al., 2011; Leong Abdullah et al., 2015). Higher degree of PTG is associated with greater appreciation of life, improved relationship with others, elevated personal strength, higher spiritual development, and/or increase possibilities in life among cancer patients (Calhoun and Tedeschi, 2006). In addition, PTG is also positively correlated with health-related quality of life (Tomich and Helgeson, 2012; Casellas-Grau et al., 2017) and long-term cancer survivors also reported to have moderate to high level of PTG (Liu et al., 2021). PTG is an important positive psychological change that merits further investigation among HNC patients since it inversely correlates with depression and psychological distress (Shand et al., 2015; Casellas-Grau et al., 2017). However, most of the studies of PTG in cancer patients were cross-sectional in design and are unable to determine how PTG and associated psychological complications varied over time. Interestingly, in a prospective study which investigated the relationship between PTG and depressive symptoms in breast cancer patients across two timelines (between the time of diagnosis and 2 years later) reported that depressive symptoms present at the time of diagnosis may facilitate development of PTG provided that depressive symptoms were elevated at the initial period after cancer diagnosis (Romeo et al., 2020).

Various predictors of PTG have been identified in studies on different cancer types. Hope is a goal-directed motivational state which enables one to have a positive outlook in life (Snyder et al., 1991). Hope contributes to several positive outcomes in cancer patients. Higher hope is associated with higher degree of positive psychology, such as PTG, optimism, resilience, and psychosocial adjustment in cancer patients (Hou et al., 2010; Ho et al., 2011; Ryu and Yi, 2013). Conversely, greater hope is negatively associated with depression, anxiety, and psychological distress (Lai et al., 2003; Yang et al., 2014). In the context of Malaysian cancer patients, hope is the most significant associated factor which predicts PTG (Leong Abdullah et al., 2019).

Coping is a behavioral and cognitive process used to tolerate, reduce, or manage the experience of a stressful event (Rajandram et al., 2011). One method of classifying coping strategies is to broadly categorize coping into approach and avoidance categories (Daisuke and Ayumi, 2016). Coping strategies in cancer patients play a pivotal role as higher level of approach coping, such as acceptance and emotional support predicted higher degree of health-related quality of life and lower degree of depression and anxiety. On the other hand, higher level of avoidance coping, such as denial and self-blaming contributed to lower degree of health-related quality of life and higher degree of depression and anxiety (Nipp et al., 2016). PTG studies on various cancer types have reported that approach coping strategies (such as positive reappraisal and acceptance), as well as religious coping, predict PTG among cancer survivors (Shand et al., 2015; Casellas-Grau et al., 2017). Besides, fatalistic attitude (the belief that regardless of any actions performed, events are predestined to happen) is also associated with higher degree of PTG in breast cancer patients (Romeo et al., 2019). Nevertheless, most of these studies focused on breast cancer and used a cross-sectional design.

In the context of HNC cancer survivors, only two studies had examined the relationship between coping strategies and benefit finding (BF), which indicated that approach coping strategies (such as positive reappraisal, active coping, and emotional support) predicted BF (Harrington et al., 2008; Llewellyn et al., 2013). PTG is distinct from BF; the latter is a process of finding positivity in response to an adverse life event in the form of a perceived benefit, whereas the former involves more pervasive cognitive changes following a traumatic event, shattering assumptions about life (Shand et al., 2015). Moreover, a study on PTG and BF that compared rural and non-rural lung cancer survivors reported that rural survivors had higher PTG than non-rural survivors, whereas no difference was found in BF between the two groups, indicating that PTG and BF are indeed two different constructs (Andrykowski et al., 2017). To the best of our knowledge, to date, no longitudinal studies had investigated how coping strategies relate to PTG

over time among HNC survivors. This study aimed to evaluate PTG trends and coping over 5–7 months among a cohort of HNC patients within the first year after their diagnosis. It determined an association between coping strategies and PTG over time.

# MATERIALS AND METHODS

## Study Design and Respondents

This longitudinal study was conducted from January 2019 to December 2020. Its participants were HNC patients registered in the otorhinolaryngology and oncology unit of the Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), and the Universiti Kebangsaan Malaysia Medical Centre (UKMMC). These two university hospitals were selected since these centers are two of the major tertiary referral centers for oncology patients in northern and central Peninsular Malaysia. The sample size required for this study was estimated based on the sample size needed to compare the difference between two dependent means using the G\*Power 3.1.9.7 calculator. The following parameters were used for the study's sample size calculation: effect size = 0.231 (based on a prospective study on PTG among HNC patients over 6 months by Leong Abdullah et al., 2015), type I error ( $\alpha$ )=0.05, and power (1- $\beta$ )=0.8. Therefore, the estimated sample size required for this study was 195 (with the addition of a 30% dropout rate).

Consecutive sampling was employed to recruit suitable subjects for this study. All HNC patients who had attended clinic and day care sessions at AMDI, USM, and UKMMC were approached by the study's research assistant, who was not directly involved in this study, and screened for eligibility criteria. The inclusion criteria included patients who: (1) had been diagnosed with HNC and who had obtained a histopathological report within 1 year after diagnosis, (2) were experiencing any stage of HNC, and (3) were 18 years old and over. Meanwhile, patients were excluded from the study if they: (1) presented with any history of pre-existing psychiatric illnesses (such as psychotic disorders, depressive disorders, anxiety disorders, bipolar mood disorder, obsessivecompulsive disorder, trauma-related disorders, substance or alcohol use disorders, and substance- or alcohol-related disorders; screened by the research team's psychiatrist using the Diagnostic and Statistical Manual for Mental Disorders, 5th Edition; American Psychiatric Association, 2013), (2) had a history of pre-existing medical illnesses, or (3) were physically too weak to answer questionnaires. HNC patients who met all of the study's inclusion criteria and none of the exclusion criteria were invited to participate in the study. Patients who voluntarily agreed to participate were explained the study's procedures, purposes, participation benefits and risks, and assurance of anonymity, as well as their right to withdraw from the study at any point of time, before signing an informed consent form. This study was approved by the Human Ethics Committee of Universiti Sains Malaysia and the Medical Research Committee of Universiti Kebangsaan Malaysia Medical Centre, and it abided by the regulations

of the 1964 Declaration of Helsinki and its subsequent amendments.

## Data Collection and Measures Data Collection

Data were collected at two time points, during baseline assessments and follow-up assessments (5–7 months after baseline assessments). All respondents were administered a socio-demographic and clinical characteristics questionnaire, the Malay version of the "PTG Inventory-Short Form" (PTGI-SF), and the Malay version of the "Brief Coping Orientation to Problems Experienced Inventory" (Brief COPE) during their baseline assessments. The question about treatment modalities, the Malay version of the PTGI-SF and the Malay version of the Brief COPE were re-administered to respondents during their follow-up assessments.

### Measures

### **Outcome** Measure

The Malay version of the PTGI-SF was administered to all respondents in order to assess PTG levels. The "PTG Inventory" (PTGI) is a self-reported instrument comprising 21 items in five domains (appreciation of life, spiritual growth, increased personal strength, new possibilities in life, and improved relationship with others). The "PTGI-SF" is a shorter version of the PTGI, comprising 10 items in five similar domains (two items per domain). It can replace the PTGI without any loss of information. Each item is scored on a Likert scale, ranging from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Thus, the PTGI-SF's total scores range from 0 to 50. The higher the total score, the greater the degree of PTG a respondent has experienced. The PTGI-SF exhibits good psychometric properties and offers the advantage of shorter administration time than the PTGI (Cann et al., 2010). The Malay version of the PTGI-SF was validated with Malaysian cancer patients, and it demonstrated good internal consistency with Cronbach's  $\alpha = 0.89$  (Leong Abdullah et al., 2017).

### **Explanatory** Variables

The Malay version of the Brief COPE was administered to respondents in order to measure the coping strategies used by HNC patients in response to cancer as a stressful event. The Brief COPE is a self-reported instrument and a shorter version of the 60-item COPE scale. It is often used in healthcare settings to assess how patients with a life-threatening medical illness cope with a stressful condition, including cancer (Hagan et al., 2017). The Brief COPE comprises 28 items in 14 subscales, such as positive reframing, active coping, self-distraction, denial, substance use, use of emotional support, behavioral disengagement, venting, planning, humor, acceptance, religious coping, self-blame, and use of instrumental support. Each item is scored on a Likert scale, ranging from 1 to 4. Thus, the total scores for each subscale range from 2 to 8. The Brief COPE subscales can be further categorized into two broad coping styles: avoidant coping (comprising selfdistraction, denial, substance use, behavioral disengagement, self-blame, and venting) and approach coping (comprising positive reframing, active coping, use of emotional support, planning, acceptance, and use of instrumental support). The Brief COPE exhibits good psychometric properties (Carver, 1997). It was validated with the Malaysian cancer population, and its subscales' internal consistency ranged from Cronbach's  $\alpha$  of 0.51–0.99 (Yusoff et al., 2009).

# Confounding Socio-Demographic and Clinical Characteristics

The study's data collected during participants' baseline and follow-up assessments on socio-demographic and clinical characteristics included gender, age, religion, time since diagnosis, stage of cancer, and cancer treatment received. The clinical data's reliability was confirmed through access to all respondents' case notes. The response options for gender were recorded as male or female. The choices for age were reported as 18-25, 26-45, 45-60 years, or more than 60 years. Responses to religion were recorded as Islam, Buddhism, Hinduism, or Christianity. The options for time since diagnosis were reported as less than 6 or 6-12 months. The responses to stage of cancer were recorded as stage 1, stage 2, stage 3, or stage 4. The responses to cancer treatment received were reported as: no treatment received; surgery only; chemotherapy only; surgery and chemotherapy; surgery and radiotherapy; chemotherapy and radiotherapy; or surgery, chemotherapy, and radiotherapy.

## **Statistical Analysis**

All data were analyzed using the Statistical Package for Social Sciences, version 26 (SPSS 26; SPSS Inc., Chicago, Illinois, United States). Descriptive statistics for socio-demographic and clinical characteristics, as well as the total PTGI-SF subscales and Brief COPE scores, were reported. All categorical variables (*gender, age, religion, time since diagnosis, stage of cancer,* and *cancer treatment received*) during baseline and follow-up assessments were reported by frequency and percentage. Meanwhile, all the continuous variables (total PTGI-SF and the Brief COPE subscales' score) were reported as means and standard deviations. The difference in total PTGI-SF and Brief COPE subscale scores between baseline and follow-up assessments were evaluated using a paired *t*-test.

The associations between socio-demographic and clinical variables, and the Brief COPE subscales (independent variables) and total PTGI-SF scores (dependent variables) across baseline and follow-up assessments, were measured using the repeated-measure, mixed-effect model. A random-intercept model was employed since the study's various measures were not assessed on a pre-determined schedule. The random-intercept model fits a separate intercept and regression line for each respondent, allowing intercepts to vary. The scores for the dependent variables for each observation were, therefore, predicted by the intercepts, which varied across groups. Thus, this approach allowed the effects of all independent variables upon the dependent variables to be evaluated at any point of time between the baseline and follow-up assessments. The statistical significance was p < 0.05, and all p values were two-sided.

# RESULTS

# **Respondent Characteristics**

Initially, 225 respondents were enrolled in the study. However, only 200 respondents completed the follow-up assessment, while 25 respondents dropped out due to various reasons (such as death, incomplete data, and refusal to participate in follow-up assessment). Thus, the study's response rate was 89%. All respondents' socio-demographic and clinical characteristics are summarized in Table 1. Slightly more than half of our respondents were male and in the 45-60-year age group. The majority of our respondents were Muslim. Slightly more than half of our respondents had been diagnosed with HNC less than 6 months prior to the study and were experiencing a more advanced stage of cancer (stages 3 or 4). The most common cancer treatment modalities received among participants during their baseline assessments were chemotherapy and radiotherapy, which modalities remained the most common during follow-up assessments.

 TABLE 1
 Socio-demographic and clinical characteristics of the respondents.

Variables         Frequency (n)         Percentage (%)           Gender         Male         109         54.5           Female         91         45.5           Age         101         101           18-25 years         7         3.5           26-45 years         48         24.0           45-60 years         48         24.0           45-60 years         104         52.0           > 60 years         41         20.5           Religion         12         16.0           Islam         149         74.5           Buddhism         32         16.0           Hinduism         13         6.5           Christianity         6         3.0           Time since diagnosis         113         56.5           6-12 months         87         43.5           Stage of cancer:         113         56.5           Stage 1         43         21.5           Stage 2         54         27.0           Stage 3         65         32.5           Stage 4         38         19.0           No treatment modalities received (baseline)         12.0           Chemotherapy only			
Male         109         54.5           Female         91         45.5           Age         18–25 years         7         3.5           26–45 years         48         24.0           45–60 years         104         52.0           > 60 years         104         52.0           > 60 years         41         20.5           Religion         149         74.5           Buddhism         32         16.0           Hinduism         13         6.5           Christanity         6         3.0           Time since diagnosis	Variables	Frequency (n)	Percentage (%)
Female         91         45.5           Age         18-25 years         7         3.5           26-45 years         48         24.0           45-60 years         104         52.0           > 60 years         104         52.0           > 60 years         41         20.5           Religion         149         74.5           Buddhism         32         16.0           Hinduism         13         6.5           Christianity         6         3.0           Time since diagnosis         113         56.5           < 6 months	Gender		
Age           18–25 years         7         3.5           26–45 years         48         24.0           45–60 years         104         52.0           > 60 years         41         20.5           Religion         149         74.5           Buddhism         32         16.0           Hinduism         13         6.5           Christianity         6         3.0           Time since diagnosis	Male	109	54.5
18-25 years         7         3.5           26-45 years         48         24.0           45-60 years         104         52.0           > 60 years         41         20.5           Religion         149         74.5           Buddhism         32         16.0           Hinduism         13         6.5           Christianity         6         3.0           Time since diagnosis         -         -           < 6 months	Female	91	45.5
26-45 years       48       24.0         45-60 years       104       52.0         > 60 years       41       20.5         Religion	Age		
45-60 years       104       52.0         > 60 years       41       20.5         Religion       149       74.5         Buddhism       32       16.0         Hinduism       13       6.5         Christianity       6       3.0         Time since diagnosis       5         < 6 months	18–25 years	7	3.5
> 60years         41         20.5           Religion	26–45 years	48	24.0
Religion         149         74.5           Islam         149         74.5           Buddhism         32         16.0           Hinduism         13         6.5           Christianity         6         3.0           Time since diagnosis	45–60 years		
Islam         149         74.5           Buddhism         32         16.0           Hinduism         13         6.5           Christianity         6         3.0           Time since diagnosis         -         -           < 6 months	> 60 years	41	20.5
Buddhism         32         16.0           Hinduism         13         6.5           Christianity         6         3.0           Time since diagnosis             < 6 months	Religion		
Hinduism       13       6.5         Christianity       6       3.0         Time since diagnosis       -         < 6 months	Islam	149	74.5
Christianity         6         3.0           Time since diagnosis         -           < 6 months	Buddhism	32	16.0
Time since diagnosis           < 6 months	Hinduism		
< 6 months	Christianity	6	3.0
6-12 months       87       43.5         Stage of cancer:	Time since diagnosis		
Stage of cancer:           Stage 1         43         21.5           Stage 2         54         27.0           Stage 3         65         32.5           Stage 4         38         19.0           Treatment modalities received (baseline)           No treatment         25         12.5           Surgery only         24         12.0           Chemotherapy only         38         19.0           Surgery and chemotherapy         13         6.5           Surgery and radiotherapy         25         12.5           Chemotherapy and radiotherapy         22         26.0           Chemotherapy, radiotherapy, and surgery         23         11.5           Treatment modalities received (follow up)         7         3.5           Chemotherapy only         7         3.5           Chemotherapy only         28         14.0           Surgery and chemotherapy         23         11.5           Surgery and radiotherapy         24         12.0	< 6 months	113	56.5
Stage 1       43       21.5         Stage 2       54       27.0         Stage 3       65       32.5         Stage 4       38       19.0         Treatment modalities received (baseline)         No treatment       25       12.5         Surgery only       24       12.0         Chemotherapy only       38       19.0         Surgery and chemotherapy       13       6.5         Surgery and radiotherapy       25       12.5         Chemotherapy and radiotherapy       25       12.5         Chemotherapy and radiotherapy       52       26.0         Chemotherapy, radiotherapy, and surgery       23       11.5         Treatment modalities received (follow up)       7       3.5         Chemotherapy only       7       3.5         Chemotherapy only       28       14.0         Surgery and chemotherapy       23       11.5         Surgery and chemotherapy       23       11.5         Surgery and chemotherapy       24       12.0         Chemotherapy and radiotherapy       23       11.5         Surgery and chemotherapy       23       11.5         Surgery and radiotherapy       24       1	6–12 months	87	43.5
Stage 2       54       27.0         Stage 3       65       32.5         Stage 4       38       19.0         Treatment modalities received (baseline)         No treatment       25       12.5         Surgery only       24       12.0         Chemotherapy only       38       19.0         Surgery and chemotherapy       13       6.5         Surgery and radiotherapy       25       12.5         Chemotherapy and radiotherapy       25       12.5         Chemotherapy and radiotherapy       25       12.5         Chemotherapy and radiotherapy       52       26.0         Chemotherapy, radiotherapy, and surgery       23       11.5         Treatment modalities received (follow up)       7       3.5         Chemotherapy only       7       3.5         Chemotherapy only       28       14.0         Surgery and chemotherapy       23       11.5         Surgery and radiotherapy       24       12.0         Chemotherapy and radiotherapy       73       36.5	Stage of cancer:		
Stage 3       65       32.5         Stage 4       38       19.0         Treatment modalities received (baseline)         No treatment       25       12.5         Surgery only       24       12.0         Chemotherapy only       38       19.0         Surgery and chemotherapy       38       19.0         Surgery and chemotherapy       24       12.0         Chemotherapy only       38       19.0         Surgery and chemotherapy       13       6.5         Surgery and radiotherapy       25       12.5         Chemotherapy and radiotherapy       52       26.0         Chemotherapy, radiotherapy, and surgery       23       11.5         Treatment modalities received (follow up)       7       3.5         Chemotherapy only       7       3.5         Chemotherapy only       28       14.0         Surgery and chemotherapy       23       11.5         Surgery and chemotherapy       23       11.5         Surgery and radiotherapy       24       12.0         Chemotherapy and radiotherapy       73       36.5	Stage 1	43	21.5
Stage 4         38         19.0           Treatment modalities received (baseline)         Image: Stage 4         Image: Stage 4	Stage 2	54	27.0
Treatment modalities received (baseline)No treatment2512.5Surgery only2412.0Chemotherapy only3819.0Surgery and chemotherapy136.5Surgery and chemotherapy2512.5Chemotherapy and radiotherapy5226.0Chemotherapy, radiotherapy, and surgery2311.5Treatment modalities received (follow up)Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and chemotherapy2412.0Chemotherapy and radiotherapy7336.5	Stage 3	65	32.5
No treatment         25         12.5           Surgery only         24         12.0           Chemotherapy only         38         19.0           Surgery and chemotherapy         13         6.5           Surgery and radiotherapy         25         12.5           Chemotherapy and radiotherapy         52         26.0           Chemotherapy, radiotherapy, and surgery         23         11.5           Treatment modalities received (follow up)         7         3.5           Chemotherapy only         7         3.5           Chemotherapy only         28         14.0           Surgery and chemotherapy         23         11.5           Surgery and chemotherapy         24         12.0           Chemotherapy and radiotherapy         24         12.0           Chemotherapy and radiotherapy         73         36.5			19.0
Surgery only2412.0Chemotherapy only3819.0Surgery and chemotherapy136.5Surgery and radiotherapy2512.5Chemotherapy and radiotherapy5226.0Chemotherapy, radiotherapy, and surgery2311.5Treatment modalities received (follow up)Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and chemotherapy2412.0Chemotherapy and radiotherapy7336.5	Treatment modalities received (baselin	ie)	
Chemotherapy only3819.0Surgery and chemotherapy136.5Surgery and radiotherapy2512.5Chemotherapy and radiotherapy5226.0Chemotherapy, radiotherapy, and surgery2311.5Treatment modalities received (follow up)Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and chemotherapy2412.0Chemotherapy and radiotherapy7336.5	No treatment	25	12.5
Surgery and chemotherapy136.5Surgery and radiotherapy2512.5Chemotherapy and radiotherapy5226.0Chemotherapy, radiotherapy, and surgery2311.5Treatment modalities received (follow up)Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and chemotherapy2311.5Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5			
Surgery and radiotherapy2512.5Chemotherapy and radiotherapy5226.0Chemotherapy, radiotherapy, and surgery2311.5Treatment modalities received (follow up)73.5Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and chemotherapy2311.5Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5			
Chemotherapy and radiotherapy5226.0Chemotherapy, radiotherapy, and surgery2311.5Treatment modalities received (follow up)73.5Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5	<b>o</b> ,		
Chemotherapy, radiotherapy, and surgery2311.5Treatment modalities received (follow up)73.5Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5			
Treatment modalities received (follow up)Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5			
Surgery only73.5Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5			11.5
Chemotherapy only2814.0Surgery and chemotherapy2311.5Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5	•	••	0.5
Surgery and chemotherapy2311.5Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5			
Surgery and radiotherapy2412.0Chemotherapy and radiotherapy7336.5			
Chemotherapy 73 36.5			
	Chemotherapy, radiotherapy, and surgery	45	22.5

Variables	Baseline a	ssessment	Follow up a	Follow up assessment	
	Mean	SD	Mean	SD	<i>t</i> test
Total PTGI-SF	33.7	11.5	39.5	9.3	< 0.001*
Brief COPE domains:					
Active coping	6.34	1.39	6.81	1.31	0.001*
Planning	6.01	1.57	6.42	1.33	0.002*
Positive reframing	6.72	1.37	7.19	1.24	< 0.001*
Acceptance	6.74	1.32	7.01	1.08	0.019*
Humor	3.24	1.64	3.41	2.00	0.338
Religious coping	7.17	1.35	7.48	0.99	0.010*
Emotional support	6.62	1.50	7.07	1.23	0.001*
Instrumental support	6.43	1.49	6.87	1.27	0.001*
Self-distraction	5.97	1.63	6.29	1.29	0.024*
Denial	3.66	1.69	3.04	1.47	< 0.001*
Venting	3.99	1.41	4.03	1.32	0.729
Substance use	2.15	0.78	2.04	0.28	0.069
Behavioral disengagement	2.71	1.28	2.54	1.15	0.151
Self-blame	2.87	1.35	2.82	1.13	0.635

TABLE 2 | Mean total Posttraumatic Growth Inventory-Short Form (PTGI-SF) and Brief Coping Orientation to Problems Experienced Inventory (Brief COPE) domain scores during baseline and follow up assessment among the respondents.

\*Statistical significance at p<0.05.

## Trend of Total PTGI-SF and Brief COPE Subscales Scores Across Baseline and Follow-Up Assessments

The total mean PTGI-SF score significantly increased between the baseline and follow-up assessments (mean baseline score = 33.7, SD = 11.5; mean follow-up score = 39.5, SD = 9.3; p < 0.001). For the Brief COPE subscales scores, the mean score for active coping (p=0.001), planning (p=0.002), positive reframing (p < 0.001), acceptance (p = 0.019), religious coping (p = 0.010), emotional support (p=0.001), instrumental support (p=0.001), and *self-distraction* (p=0.024) significantly increased between the baseline and follow-up assessments. Additionally, religious coping (p=0.010) also significantly increased from baseline to follow-up. In contrast, the mean score for *denial* (p < 0.001) significantly decreased between baseline and follow-up assessments. The mean scores for the total PTGI-SF and Brief COPE subscales during baseline and follow-up assessments, and the value of p of the paired t-test between baseline and follow-up, are presented in Table 2.

## Socio-Demographic and Clinical Variables and the Brief Cope Subscales' Effects on Respondents' Total PTGI-SF Between Baseline and Follow-Up Assessments

The random-intercept models between the socio-demographic and clinical characteristics, and between the Brief COPE domain scores (independent variables) and total PTGI-SF scores (dependent variable), are summarized in **Table 3**. The study's repeated-measure, mixed-effect model revealed that only three Brief COPE subscales significantly predicted respondents' total PTGI-SF scores between their baseline and follow-up assessments after controlling for relevant socio-demographic and clinical factors. A higher degree of coping by *planning* (estimate=1.256, 95% CI=0.378-2.134, SE=0.447, t=2.811, p=0.005) and a higher degree of *coping by acceptance* (estimate = 1.162, 95% CI = 0.188-2.136, SE = 0.495, t=2.346, p=0.019) significantly predicted higher PTG. Meanwhile, a higher degree of *coping by denial* (estimate = -1.078, 95% CI = -1.793 to -0.364, SE = 0.363, t=-2.966, p=0.003) significantly contributed to lower PTG.

As for socio-demographic characteristics, male HNC respondents registered a significantly lower degree of PTG compared with female HNC respondents across time (estimate = -2.975, 95% CI = -5.201 to -0.749, SE = 1.129, t = -2.635, p = 0.009), whereas those aged above 60 years old exhibited a significantly higher degree of PTG compared with those aged 18-40 years old (estimate = 6.479, 95% CI = 0.860-12.098, SE = 2.850, t = 2.273, p = 0.024). Treatment modalities received was the only clinical characteristic associated with PTG across time, whereby those who received chemotherapy only (estimate = 6.015, 95% CI = 1.262-10.768, SE = 2.418, t = 2.488, p = 0.013), surgery and chemotherapy (estimate = 5.503, 95%) CI = 0.194 - 10.812, SE = 2.700, t = 2.038, p = 0.042), and chemotherapy and radiotherapy (estimate = 5.174, 95% CI = 0.866-9.483, SE = 2.191, t = 2.362, p = 0.019) demonstrated significantly higher degree of PTG compared with those who were treated with surgery only (Table 3).

## DISCUSSION

This study investigated PTG and coping trends across 5–7 months among a cohort of HNC patients within the first year after their diagnosis. It determined coping strategies' effect on PTG over time. We found that PTG and approach coping (active coping, planning, positive reframing, acceptance, emotional support, and instrumental support) increased while avoidant coping (self-distraction and denial) decreased over time (from baseline to follow-up). Moreover, two approach coping TABLE 3 | The random intercept model between the socio-demographic and clinical characteristics, and the Brief COPE domain scores (independent variables), and total PTGI-SF scores (dependent variable).

Variables	Estimate (95% CI)	SE	t	Value of p
Gender				
Female	Reference			
Male	-2.975 (-5.201 to -0.749)	1.129	-2.635	0.009*
Age			21000	0,000
18–40 years	Reference			
41–60 years	4.369 (-0.871 to 9.610)	2.658	1.644	0.102
> 60 years	6.479 (0.860–12.098)	2.850	2.273	0.024*
Religion	0.473 (0.000-12.030)	2.000	2.210	0.024
•	Defenses			
Christianity		0.047	0.000	0.400
Islam Buddhism	2.097 (-3.908 to 8.102)	3.047	0.688	0.492 0.197
Budanism Hinduism	4.234 (-2.210 to 10.679)	3.269	1.295	0.197 0.628
	1.782 (-5.447 to 9.010)	3.667	0.486	0.628
Time since diagnosis				
< 6 months	Reference	4.450	0.550	0.575
6 months to 12 months	0.647 (-1.632 to 2.926)	1.156	0.559	0.577
Stage of cancer				
Stage 1	Reference			
Stage 2	2.677 (-0.410 to 5.764)	1.566	1.710	0.089
Stage 3	1.986 (–1.147 to 5.118)	1.589	1.250	0.213
Stage 4	1.790 (-1.654 to 5.233)	1.747	1.025	0.307
Treatment modalities received				
No treatment	Reference			
Surgery only	1.598 (-3.641 to 6.837)	2.665	0.600	0.549
Chemotherapy only	6.015 (1.262 to 10.768)	2.418	2.488	0.013*
Surgery and chemotherapy	5.503 (0.194 to 10.812)	2.700	2.038	0.042*
Surgery and radiotherapy	1.134 (-3.934 to 6.201)	2.578	0.440	0.660
Chemotherapy and radiotherapy	5.174 (0.866–9.483)	2.191	2.362	0.019*
Chemotherapy, radiotherapy,	3.360 (-1.385 to 8.104)	2.413	1.392	0.165
and surgery				
The Brief COPE domains				
Active coping	-0.159 (-0.985 to 0.667)	0.420	-0.378	0.705
Planning	1.256 (0.378 to 2.134)	0.447	2.811	0.005*
Positive reframing	0.608 (-0.484 to 1.699)	0.555	1.094	0.275
Acceptance	1.162 (0.188 to 2.136)	0.495	2.346	0.019*
Humor	-0.186 (-0.759 to 0.387)	0.291	-0.638	0.524
Religious coping	0.756 (-0.196 to 1.707)	0.484	1.561	0.119
Emotional support	0.384 (-0.736 to 1.504)	0.570	0.674	0.501
nstrumental support	0.175 (-0.894 to 1.245)	0.544	0.322	0.748
Self-distraction	-0.021 (-0.816 to 0.774)	0.404	-0.052	0.958
Denial	-1.078 (-1.793 to -0.364)	0.363	-2.966	0.003*
Venting	0.010 (-0.823 to 0.843)	0.424	0.023	0.982
Substance use	0.804 (-1.117 to 2.725)	0.977	0.823	0.411
Behavioral disengagement	0.712 (-0.299 to 1.724)	0.515	1.385	0.167
Self-blame	-0.287 (-1.219 to 0.644)	0.474	-0.607	0.544

\*Statistical significance at p<0.05.

styles – namely, planning and acceptance – contributed to higher PTG over time. On the contrary, one avoidant coping style – namely, denial – precipitated lower PTG over time among HNC respondents after controlling for socio-demographic and clinical characteristics.

The increasing PTG trend among HNC patients has been well-documented during their first 18 months of cancer diagnosis (Harding, 2018a). Our findings confirmed the PTG trend during patients' first 18 months after diagnosis since our respondents had been diagnosed with cancer with the past 12 months of the study, and the time interval between their baseline and

follow-up assessments was 5–7 months; thus, respondents had been diagnosed up to 18 months previously to their follow-up assessments in this study. Further, the trend of coping over time after an initial cancer diagnosis in our findings confirmed the findings of previous studies with cancer patients, in which approach coping – such as acceptance, active coping, positive reframing (through positive cognitive restructuring), and seeking emotional and informational support – and religious coping increased over time, whereas avoidant coping (such as denial and self-distraction) depreciated gradually as acceptance increased (Sajadian et al., 2017). Moreover, another study evaluating coping among HNC survivors also indicated that positive reframing, active coping, religious coping, and seeking emotional support from family and friends are common coping strategies after diagnosis (Jagannathan and Juvva, 2016).

Our findings revealed that approach coping helped increase PTG over time. For instance, a higher degree of acceptance significantly enhanced respondents' PTG. To the best of our knowledge, to date, our study is the first to confirm the acceptance's positive effect on PTG among HNC survivors. This positive relationship between acceptance and PTG was further strengthened by similar findings that have been reported among breast cancer survivors, which indicated that acceptance lowers perceived stress and, in turn, enhances PTG over time (Bussell and Naus, 2010). Moreover, longitudinal study in cancer patients also reported that problem-focus coping (coping by direct confrontation of stress to reduce or eliminate it, which is similar to approach coping) and active-adaptive coping predicted higher degree of PTG over time (Scrignaro et al., 2011; Danhauer et al., 2015). This finding supported the theoretical model suggesting that PTG is an adaptive process of cognitively processing a traumatic event, during which approach coping may moderate PTG (Bussell and Naus, 2010). Thus, we propose that acceptance of the traumatic event (cancer diagnosis) is an important initial process (Prati and Pietrantoni, 2009) that allows the cognitive reappraisal of the traumatic (cancer) experience before a successful search for meaning in the trauma can facilitate PTG development among cancer survivors.

Interestingly, a higher degree of planning for ways to cope with and manage the stressful event of cancer also tends to enhance PTG over time, as our study has highlighted. Greater hope has been reported to predict higher levels of PTG among HNC patients (Ho et al., 2011). Hope is associated with positive beliefs and attitudes about posttraumatic worldviews in relation to the self, others, and the surrounding world. Greater hope facilitates cognitive reappraisal, allowing HNC patients to rethink the discrepancies between their pre-trauma and post-trauma worldviews, incorporate new trauma-related information, and form a new posttraumatic worldview of the self, others, and the surrounding world via accommodation, therefore facilitating the PTG development among cancer survivors (Leong Abdullah et al., 2019). The planning coping strategy and pathway component of hope share similarities (the perceived ability to generate ways and paths to achieve a goal-set). A previous study of HNC survivors also identified that the pathway component of hope was particularly associated with increased PTG (Ho et al., 2011). Our study's HNC survivors may have exhibited a high level of hope's pathway component, increasing their tendency to plan for ways to cope with and manage the stressful event of cancer and, in turn, facilitating PTG development.

Unsurprisingly, a higher degree of coping by denial lowered the degree of PTG among HNC survivors over time. There is a growing body of literature indicating that avoidant coping contributes to lower degree of PTG among cancer patients (Kroemeke et al., 2017; Li et al., 2019). Denial about having cancer and cancer's negative consequences may have occurred at a higher degree immediately after cancer diagnoses. Denial or self-deception may have allowed patients to shift their perceptions from losses to benefits, thereby consolidating and maintaining an assumptive worldview of the self, others, and the surrounding world in response to trauma, facilitating the development of PTG's illusory aspect to counteract the emotional distress stemming from their traumatic events. This cognitive avoidance coping disrupts the cognitive reappraisal of cancer as a traumatic event and encourages the avoidance of a search for meaning in the traumatic event. Consequently, though denial may offer short-term relief of emotional distress, it is maladaptive over the long term, preventing the development of the PTG's constructive aspect (Zoellner and Maercker, 2006; Ochoa Arnedo et al., 2019). This finding may explain the inverse relationship between denial and PTG among this study's respondents.

As for the association between socio-demographic characteristics and PTG in cancer patients, gender was reported to be associated with PTG, wherein females tend to exhibit higher degree of PTG than males (Shand et al., 2015; Sharp et al., 2018; Leong Abdullah et al., 2019). Similar finding was also reported among HNC patients (Holtmaat et al., 2017) and the finding of our study further strengthened the association between female cancer patients and higher degree of PTG. It has been suggested that females tend to engage in cognitive reprocessing of the trauma-related experience, initiate search for meaning out of the traumatic experience and thus, increasing the likelihood of developing PTG as compared to males (Leong Abdullah et al., 2019). Besides gender, this study also revealed that older HNC patients (above 60 years old) had greater degree of PTG compared with younger patients. This contradicts the finding of a longitudinal study in breast cancer patients which documented patients of younger age group had higher degree of PTG (Danhauer et al., 2015). But in the context of HNC patients, no published studies have found an impact of age on PTG (Harding, 2018b). Hence, the relationship between age and PTG in cancer patients remains inconsistent.

Several studies have investigated the association between cancer treatment modalities (chemotherapy, radiotherapy, and surgery) and PTG among cancer patients (Tanyi et al., 2017). Among the modalities of treatment, chemotherapy has been shown to be a significant predictor of higher PTG among cancer patients across time (Danhauer et al., 2015). Our findings were consistent with that of other study as HNC patients who received chemotherapy, either as monotherapy or in combination with other treatment modalities, experienced higher PTG over time compared with those who were on surgery alone. Chemotherapy may greatly disrupt the daily living and induced significant degree of stress among the HNC patients due to the adverse effects associated with this treatment modality. This may initiate the adaptive processes to search for meaning out of their stressful experience and enable positive psychological changes such as PTG to develop among the HNC respondents in our study (Danhauer et al., 2015). Regarding other socio-demographic and clinical characteristics, such as religion, time since diagnosis, and stage of cancer, they were no association between them and PTG in cancer

patients as indicated by other longitudinal studies (Danhauer et al., 2013, 2015; Leong Abdullah et al., 2015).

Our findings should be interpreted alongside a consideration of a few limitations. First, respondents' socio-demographic characteristics in this study may not sufficiently represent Malaysia's HNC patient population. This limitation affects our findings' generalizability. Finally, although we proposed that the effect of coping by planning on a higher degree of PTG may be mediated by hope's pathway component, we did not assess hope in this study. Therefore, we recommend that future longitudinal studies assess the relationship between coping, hope, and PTG.

Notwithstanding these limitations, this study is the first longitudinal study in HNC survivors to evaluate how coping styles vary over time, as well as coping styles' effect on PTG over time. Our findings suggest that treating clinicians must incorporate psychosocial interventions that effectively increase acceptance and reduce denial into their treatment regimes for HNC patients, such as acceptance and commitment therapy (ACT; Dindo et al., 2017; Zhao et al., 2021). ACT facilitates the development of greater psychological flexibility by increasing adaptive coping through acceptance, cognitive diffusion, mindfulness, and perspective-taking exercises, and it supports cancer survivors' aligning their behaviors with their personal values (Johns et al., 2019). Therefore, ACT may help enhance PTG among HNC survivors by increasing acceptance and reducing denial.

As we have shown, this study was the first longitudinal study to show that approach coping (such as active coping, planning, positive reframing, acceptance, emotional support, and instrumental support) increased while avoidant coping (self-distraction and denial) decreased over time among a cohort of HNC survivors within the first year of their diagnoses. Two approach coping strategies enhanced PTG over time – namely, acceptance and planning. In contrast, the only avoidant coping that reduced PTG over time was denial. Based on our findings, we have suggested that future research investigate ACT's efficacy in enhancing PTG among HNC survivors.

## REFERENCES

- American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th Edn. Arlington, United States: American Psychiatric Publishing.
- Andrykowski, M. A., Steffens, R. F., Bush, H. M., and Tucker, T. C. (2017). Posttraumatic growth and benefit-finding in lung cancer survivors: the benefit of rural residence? *J. Health Psychol.* 22, 896–905. doi: 10.1177/ 1359105315617820
- Bussell, V. A., and Naus, M. J. (2010). A longitudinal investigation of coping and posttraumatic growth in breast cancer survivors. J. Psychosoc. Oncol. 28, 61–78. doi: 10.1080/07347330903438958
- Calhoun, L. G., Cann, A., Tedeschi, R. G., and McMillan, J. (2000). A correlational test of the relationship between posttraumatic growth, religion, and cognitive processing. J. Trauma. Stress. 13, 521–527. doi: 10.1023/A:1007745627077
- Calhoun, L. G., and Tedeschi, R. G. (2006). *Handbook of Posttraumatic Growth: Research and Practice.* Malwah NJ: Lawrence Erlbaum Associates.
- Cann, A., Calhoun, L. G., and Tedeschi, R. G. (2010). A short form of posttraumatic growth inventory. *Anxiety Stress Coping* 23, 127–137. doi: 10.1080/10615800903094273

If ACT's efficacy on PTG is documented, ACT's inclusion in HNC patients' treatment regime may be pivotal.

## DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.

## **ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Human Research Ethics Committee of USM, Division of Research & Innovation (R&I), USM Health Campus, Kubang Kerian, Kelantan, Malaysia, and the Medical Research Committee of the Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia. The patients/participants provided their written informed consent to participate in this study.

## AUTHOR CONTRIBUTIONS

ML and NN conceptualized and designed the study and involved in data and statistical analysis. ML, NN, NAH, NA, RR, RM, MM, and HZ involved in data collection. ML wrote the first draft of the manuscript. All authors contributed to the article and approved the submitted version.

## FUNDING

This work was supported by the Short Term Grant of Universiti Sains Malaysia (Grant number: 304/CIPPT/6315236; author ML). The funder has no role in the conceptualization of the review, literature review, writing of the manuscript, and decision on submission of the manuscript for publication. There was no fund received for open access publication fees.

- Carver, C. S. (1997). You want to measure coping but your protocol'too long: consider the brief cope. *Int. J. Behav. Med.* 4, 92–100. doi: 10.1207/ s15327558ijbm0401\_6
- Casellas-Grau, A., Ochoa, C., and Ruini, C. (2017). Psychological and clinical correlates of posttraumatic growth in cancer: a systematic and critical review. *Psychooncology* 26, 2007–2018. doi: 10.1002/pon.4426
- Daisuke, H., and Ayumi, E. (2016). Characteristics of coping strategies and the relationships between coping strategies and stress reactions in physical therapy students during clinical practice. J. Phys. Ther. Sci. 28, 2867–2870. doi: 10.1589/jpts.28.2867
- Danhauer, S. C., Russell, G., Case, L. D., Sohl, S. J., Tedeschi, R. G., Addington, E. L., et al. (2015). Trajectories of posttraumatic growth and associated characteristics in women with breast cancer. *Ann. Behav. Med.* 49, 650–659. doi: 10.1007/ s12160-015-9696-1
- Danhauer, S. C., Russell, G. B., Tedeschi, R. G., Jesse, M. T., Vishnevsky, T., Daley, K., et al. (2013). A longitudinal investigation of posttraumatic growth in adult patients undergoing treatment for acute leukemia. *J. Clin. Psychol. Med. Settings* 20, 13–24. doi: 10.1007/s10880-012-9304-5

- Dindo, L., Van Liew, J. R., and Arch, J. J. (2017). Acceptance and commitment therapy: a transdiagnostic behavioral intervention for mental health and medical conditions. *Neurotherapeutics* 14, 546–553. doi: 10.1007/ s13311-017-0521-3
- Globocan (2020). Malaysia Source: Globocan 2020. Available at: https://gco. iarc.fr/today/data/factsheets/populations/458-malaysia-fact-sheets.pdf (Accessed May 23, 2021).
- Hagan, T. L., Fishbein, J. N., Nipp, R. D., Jacobs, J. M., Traeger, L., Irwin, K. E., et al. (2017). Coping in patients with incurable lung and gastrointestinal cancers: a validation study of the brief COPE. J. Pain Symptom Manag. 53, 131–138. doi: 10.1016/j.jpainsymman.2016.06.005
- Harding, S. A. (2018a). The trajectory of positive psychological change in a head and neck cancer population. *Int. J. Oral Maxillofac. Surg.* 47, 578–584. doi: 10.1016/j.ijom.2017.09.010
- Harding, S. (2018b). Positive psychological change in head and neck cancer populations. J. Cancer Treatment Diagn. 2, 1–7. doi: 10.29245/2578-2967/2018/2.1126
- Harrington, S., McGurk, M., and Llewellyn, C. D. (2008). Positive consequences of head and neck cancer: key correlates of finding benefit. J. Psychosoc. Oncol. 26, 43–62. doi: 10.1080/07347330802115848
- Ho, S., Rajandram, R. K., Chan, N., Samman, N., McGrath, C., and Zwahlen, R. A. (2011). The roles of hope and optimism on posttraumatic growth in oral cavity cancer patients. *Oral Oncol.* 47, 121–124. doi: 10.1016/j. oraloncology.2010.11.015
- Holtmaat, K., van der Spek, N., Cuijpers, P., Leemans, C. R., and Verdonck-de Leeuw, I. M. (2017). Posttraumatic growth among head and neck cancer survivors with psychological distress. *Psychooncology* 26, 96–101. doi: 10.1002/pon.4106
- Hou, W. K., Law, C. C., Yin, J., and Fu, Y. T. (2010). Resource loss, resource gain, and psychological resilience and dysfunction following cancer diagnosis: a growth mixture modeling approach. *Health Psychol.* 29, 484–495. doi: 10.1037/a0020809
- Jagannathan, A., and Juvva, S. (2016). Emotions and coping of patients with head and neck cancers after diagnosis: A qualitative content analysis. J. Postgrad. Med. 62, 143–149. doi: 10.4103/0022-3859.184273
- Johns, S. A., Stutz, P. V., Talib, T. L., Cohee, A. A., Beck-Coon, K. A., Brown, L. F., et al. (2019). Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: a 3-arm pilot randomized controlled trial. *Cancer* 126, 211–218. doi: 10.1002/cncr.32518
- Kroemeke, A., Bargiel-Matusiewicz, K., and Kalamarz, M. (2017). Mixed psychological changes following mastectomy: unique predictors and heterogeneity of post-traumatic growth and post-traumatic depreciation. *Front. Psychol.* 8:1245. doi: 10.3389/fpsyg.2017.01245
- Lai, Y. H., Chang, J. T. C., Keefe, F. J., Chiou, C. F., Chen, S. C., Feng, S. C., et al. (2003). Symptom distress, catastrophic thinking, and hope in nasopharyngeal carcinoma patients. *Cancer Nurs.* 26, 485–493. doi: 10.1097/00002820-200312000-00008
- Leong Abdullah, M. F. I., Hami, R., Appalanaido, G. K., Azman, N., Mohd Shariff, N., and Md Sharif, S. S. (2017). Validation of the Malay version of the Posttraumatic Growth Inventory-Short Form (PTGI-SF) among Malaysian cancer patients. *Asian J. Psychiatr.* 18, 135–143.
- Leong Abdullah, M. F. I., Hami, R., Appalanaido, G. K., Azman, N., Mohd Shariff, N., and Md Sharif, S. S. (2019). Diagnosis of cancer is not a death sentence: examining posttraumatic growth and its associated factors in cancer patients. *J. Psychosoc. Oncol.* 37, 636–651. doi: 10.1080/07347332.2019.1574946
- Leong Abdullah, M. F. I., Nik Jaafar, N. R., Zakaria, H., Rajandram, R. K., Mahadevan, R., Mohamad Yunus, M. R., et al. (2015). Posttraumatic growth, depression and anxiety in head and neck cancer patients: examining their patterns and correlations in a prospective study. *Psychooncology* 24, 894–900. doi: 10.1002/pon.3740
- Li, J., Sun, L., Wang, X., Sun, C., Heng, S., Hu, X., et al. (2019). Are posttraumatic stress symptoms and avoidant coping inhibitory factors? The association between posttraumatic growth and quality of life among low-grade gliomas patients in China. *Front. Psychol.* 10:330. doi: 10.3389/ fpsyg.2019.00330
- Liu, Z., Thong, M. S. Y., Doege, D., Koch-Gallenkamp, L., Bertram, H., Eberle, A., et al. (2021). Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional

population-based survey in Germany. Br. J. Cancer 125, 877-883. doi: 10.1038/s41416-021-01473-z

- Llewellyn, C. D., Horney, D. J., McGurk, M., Weinman, J., Herold, J., Altman, K., et al. (2013). Assessing the psychological predictors of benefit finding in patients with head and neck cancer. *Psychooncology* 22, 97–105. doi: 10.1002/ pon.2065
- Nipp, R. D., El-Jawahri, A., Fishbein, J. N., Eusebio, J., Stagl, J. M., Gallagher, E. R., et al. (2016). The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. *Cancer* 122, 2110–2116. doi: 10.1002/ cncr.30025
- Ochoa Arnedo, C., Sánchez, N., Sumalla, E. C., and Casellas-Grau, A. (2019). Stress and growth in cancer: mechanisms and psychotherapeutic interventions to facilitate a constructive balance. *Front. Psychol.* 10:177. doi: 10.3389/ fpsyg.2019.00177
- Prati, G., and Pietrantoni, L. (2009). Optimism, social support, and coping strategies as factors contributing to posttraumatic growth: a meta-analysis. *J. Loss Trauma* 14, 364–388. doi: 10.1080/15325020902724271
- Rajandram, R. K., Jenewein, J., McGrath, C., and Zwahlen, R. A. (2011). Coping processes relevant to posttraumatic growth: an evidence-based review. Support Care Cancer 19, 583–589. doi: 10.1007/s00520-011-1105-0
- Romeo, A., Di Tella, M., Ghiggia, A., Tesio, V., Gasparetto, E., Stanizzo, M. R., et al. (2019). The traumatic experience of breast cancer: which factors can relate to the post-traumatic outcomes? *Front. Psychol.* 10:891. doi: 10.3389/ fpsyg.2019.00891
- Romeo, A., Di Tella, M., Ghiggia, A., Tesio, V., Torta, R., and Castelli, L. (2020). Posttraumatic growth in breast cancer survivors: are depressive symptoms really negative predictors? *Psychol. Trauma* 12, 244–250. doi: 10.1037/tra0000508
- Ryu, Y. M., and Yi, M. (2013). The factors influencing quality of life in women with breast cancer. Asian Oncol. Nurs. 13, 121–127. doi: 10.5388/ aon.2013.13.3.121
- Sajadian, A., Mahsa, R. L., Motaharinasab, A., Kazemnejad, A., and Haghighat, S. (2017). Breast cancer coping strategies after diagnosis: a six-month follow-up. *Multidiscip. Cancer Investig.* 1, 12–16. doi: 10.21859/ mci-01042
- Scrignaro, M., Barni, S., and Magrin, M. E. (2011). The combined contribution of social support and coping strategies in predicting post-traumatic growth: a longitudinal study on cancer patients. *Psychooncology* 20, 823–831. doi: 10.1002/pon.1782
- Shand, L. K., Cowlishaw, S., Brooker, J. E., Burney, S., and Ricciardelli, L. A. (2015). Correlates of posttraumatic stress symptoms and growth in cancer patients: a systematic review and meta-analysis. *Psychooncology* 24, 624–634. doi: 10.1002/pon.3719
- Sharp, L., Redfearn, D., Timmons, A., Balfe, M., and Patterson, J. (2018). Posttraumatic growth in head and neck cancer survivors: is it possible and what are the correlates? *Psychooncology* 27, 1517–1523. doi: 10.1002/ pon.4682
- Snyder, C. R., Harris, C., Anderson, J. R., Holleran, S. A., Irving, L. M., Sigmon, S. T., et al. (1991). The will and the ways: development and validation of an individual-differences measure of hope. *J. Pers. Soc. Psychol.* 60, 570–585. doi: 10.1037/0022-3514.60.4.570
- Tanyi, Z., Mirnics, Z., Ferenczi, A., Smohai, M., Mészáros, V., Kovács, D., et al. (2017). Cancer as a source of posttraumatic growth: a brief review. *Psychiatr. Danub.* 32, 401-411.
- Tedeschi, R. G., and Calhoun, L. G. (1996). The posttraumatic growth inventory: measuring the positive legacy of trauma. J. Trauma. Stress. 9, 455–471. doi: 10.1007/BF02103658
- Tedeschi, R. G., and Calhoun, L. G. (2004). Posttraumatic growth: conceptual foundations and empirical evidence. *Psychol. Inq.* 15, 1–18. doi: 10.1207/ s15327965pli1501\_01
- Tomich, P. L., and Helgeson, V. S. (2012). Posttraumatic growth following cancer: links to quality of life. J. Trauma. Stress. 25, 567–573. doi: 10.1002/ jts.21738
- World Health Organization (2021). Cancer. Available at: https://www.who.int/ news-room/fact-sheets/detail/cancer (Accessed May 23, 2021).
- Yang, Y. L., Liu, L., Wang, X. X., Wang, Y., and Wang, L. (2014). Prevalence and associated positive psychological variables of depression and anxiety among Chinese cervical cancer patients: a cross-sectional study. *PLoS One* 9:e94804. doi: 10.1371/journal.pone.0094804

Yusoff, N., Low, W. Y., and Yip, C. H. (2009). Reliability and validity of the Malay version of brief COPE scale: a study on Malaysian women treated with adjuvant chemotherapy for breast cancer. *Malays. J. Psychiatry* 18, 1–9.

Zhao, C., Lai, L., Zhang, L., Cai, Z., Ren, Z., Shi, C., et al. (2021). The effects of acceptance and commitment therapy on the psychological and physical outcomes among cancer patients: A meta-analysis with trial sequential analysis. J. Psychosom. Res. 140:110304. doi: 10.1016/j.jpsychores.2020.110304

Zoellner, T., and Maercker, A. (2006). Posttraumatic growth in clinical psychology—a critical review and introduction of a two component model. *Clin. Psychol. Rev.* 26, 626–653. doi: 10.1016/j.cpr.2006.01.008

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Nik Jaafar, Abd Hamid, Hamdan, Rajandram, Mahadevan, Mohamad Yunus, Zakaria and Leong Bin Abdullah. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.